Non-opioid Pain Treatment: Global Markets to 2024

Report Highlights

The global market for non-opioid pain treatments should grow from $13.8 billion in 2019 to $31.8 billion by 2024 at a compound annual growth rate (CAGR) of 18.3% for the period of 2019-2024.

Report Includes

• 44 data tables and 19 additional tables
• An overview of the global market for Non-opioid pain treatments
• Analyses of global market trends, with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
• Description of products included in this market, and a detailed analysis of the markets and market opportunities
• Information on significant products categories, issues and trends, market influences, regulatory issues and other information affecting the pain management industry
• Briefing about major drivers and regional dynamics of the market and current trends within the industry
• Comprehensive profiles of major vendors in the market, including Allergan PLC, Canopy Growth Corp., Medical Marijuana Inc., Panag Pharma Inc., and Tilray

Report Scope

This BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This study addresses acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.

The report identifies five general product segments for Non-opioid treatment of pain:

• Medical cannabis treatments.
• Capsaicin-derived treatments.
• Menthol-containing treatments.
• Omega 3 fatty acid-containing treatments.
• Botulinum toxins.

Within the segment several sub-segments are discussed as they pertain to each product segment; diseases or disorders are the basis for these sub-segments, including: 

• Arthritis.
• Cancer–brain, breast, colorectal, leukemia/lymphoma, melanoma, prostate, others.
• Dental.
• Epilepsy.
• Fibromyalgia.
• Migraine.
• Multiple sclerosis.
• Surgical.

A regional analysis of these product segments is also provided, including the specific countries listed below and including countries not listed as a “rest of the world” market.

• Argentina.
• Australia/New Zealand.
• Brazil.
• Canada.
• China.
• France.
• Germany.
• Italy.
• Japan.
• Mexico.
• Russia.
• Spain.
• United Kingdom.
• United States.

Each market segment provides detailed information based on product categories, product use, current market value and forecasts.

Not covered in the report are drugs or devices that are considered “conventional” in professional treatment guidelines that are due to either controversial issues such as those with medical cannabis or those that are not commonly prescribed or recommended due to a lack of clinical data, education or other factors.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.